De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination

Transplantation

Volumn 73, Issue 5, 2002, Pages 756-760

  Langer, Robert M ^a   Van Buren, Charles T ^a   Katz, Stephen M ^a   Kahan, Barry D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOGLOBULIN A; LACTATE DEHYDROGENASE; RAPAMYCIN; STEROID;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASPERGILLOSIS; CLINICAL ARTICLE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DEMOGRAPHY; DISEASE COURSE; DISEASE PREDISPOSITION; FEMALE; GLOMERULOPATHY; GRAFT REJECTION; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MULTIPLE ORGAN FAILURE; NEPHRECTOMY; PLASMAPHERESIS; PRIORITY JOURNAL; THROMBOCYTOPENIA; VIRUS INFECTION;

EID: 0037087662     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200203150-00017     Document Type: Article

References (34)

1. Hemolytic uremic syndrome associated with Influenza A virus infection in an adult renal allograft recipient: Case report and review of the literature
2. Nephrotexicity of cyclosporine A after allogenic marrow transplantation
3. De novo hemolytic uremic syndrome in renal transplant recipients immunosuppressed with cyclosporine
4. Recurrence of haemolytic uraemic syndrome triggered by cyclosporin A after renal transplantation
5. Cyclosporine-induced haemolyric uraemic syndrome in liver allograft recipient
6. Cyclosporine-associated thrombotic microangiopathy/hemolytic uremic syndrome following kidney and kidney-pancreas transplantation
7. Hemolytic-uremic syndrome during cyclosporine immunosuppression in renal allograft recipients
8. Cyclosporine-associated hemolytic uremic syndrome in four renal allograft recipients: Resolution without specific therapy
9. Transplant-associated thrombotic microangiopathy: The role of IgG administration as initial therapy
10. Cyclosporine-induced hemolytic uremic syndrome: Factors that obscure its diagnosis
11. De novo hemolytic uremia syndrome: A rare adverse effect in renal transplant recipients immunosuppressed with cyclosporine
12. Obliterative renal arteriopathy following cyclosporine therapy
13. Thrombotic microangiopathy in renal transplant recipients treated with cyclosporin A
14. The side-effects of ciclosporine-A and tacrolimus
15. Microvascular changes in renal allografts associated with FK506 (tacrolimus) therapy
16. Renal transplantation under cyclosporine and FK506 for hemolytic uremic syndrome
17. Hemolytic-uremic syndrome in a renal transplant recipient on FK506 immunosuppression
18. Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506
19. Haemolytic uraemic syndrome in a renal transplant recipient during OKT3 therapy
20. Early recurrence of hemolytic uremic syndrome in a renal transplant recipient during prophylactic OKT3 therapy
21. Hämolytisch-urämisches syndrom nach nierentransplantation: Prognostische fakteren
22. Microangiopathic hemolytic anemia associated with hyperacute rejection of a kidney allograft
23. Occurence of hemolytic uremic syndrome under cyclosporine treatment: Accident or possible side effect mediated by a lack of prostacyclin-stimulating plasma factor?
24. Low red cell arachidonic acid in cyclosporine-treated patients
25. Haemolytic-uraemic syndrome: Deficiency of plasma factor(s) regulating prostacyclin activity?
26. Reversal of cyclosporine-associated hemolytic-uremic syndrome by plasma exchange with fresh-frozen plasma replacement in renal transplant recipients
27. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation
28. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study
29. Hemolytic uremic syndrome in solid organ transplant recipients
30. Routine clinical monitoring of sirolimus (rapamycin) whole-blood concentrations by HPLC with ultraviolet detection
31. A worldwide, phase III randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts
32. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology
33. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: Risk factors, incidence, progression, and management
34. Cyclospotine-associated thrombotic microangiopathy in renal allografts